Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
1.36
Industry P/E
--
Debt to Equity
0
ROE
-10.93 %
ROCE
--
Div. Yield
0 %
Book Value
0.6
EPS
--
CFO
$-25.11 Mln
EBITDA
$-41.55 Mln
Net Profit
$-41.75 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| -42.24 | -1.03 | -41.74 | -91.21 | -83.75 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| -86.75 | -89.50 | -70.26 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of... lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Address: 3480 Peachtree Road NE, Atlanta, GA, United States, 30326 Read more
CEO & Director
Mr. Stephan Jackman
CEO & Director
Mr. Stephan Jackman
Headquarters
Atlanta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alzamend Neuro Inc (ALZN) stood at $ 5 Mln as on 31-Jan-25
The share price of Alzamend Neuro Inc (ALZN) is $0.67 (NASDAQ) as of 17-Apr-2025 16:02 EDT. Alzamend Neuro Inc (ALZN) has given a return of -83.75% in the last 3 years.
Alzamend Neuro Inc (ALZN) has a market capitalisation of $ 5 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Alzamend Neuro Inc (ALZN) is 1.36 times as on 17-Apr-2025, a 40% discount to its peers’ median range of 2.26 times.
Since, TTM earnings of Alzamend Neuro Inc (ALZN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alzamend Neuro Inc (ALZN) and enter the required number of quantities and click on buy to purchase the shares of Alzamend Neuro Inc (ALZN).
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Address: 3480 Peachtree Road NE, Atlanta, GA, United States, 30326
The CEO & director of Mr. Stephan Jackman. is Alzamend Neuro Inc (ALZN), and CFO & Sr. VP is Mr. Stephan Jackman.
There is no promoter pledging in Alzamend Neuro Inc (ALZN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Alzamend Neuro Inc (ALZN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-4165.73
|
|
Net Margin(%)
|
-5553.72
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Alzamend Neuro Inc (ALZN) was $0 Mln.
$-0.04
(
